How People with Pulmonary Fibrosis Decide About Continuing Antifibrotic Therapy
Interviews adults with pulmonary fibrosis about keeping or stopping antifibrotic therapy after side effects.
Plain-language title generated from the registry record
Registry title: Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis
Key facts
- Where
- Tokyo, JapanSee the site
Where in Japan
- Mebix, IncTokyo, JapanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07722507
- Record updated
- 23 July 2026
- Original description
This study will explore how adults in Japan with pulmonary fibrosis decide whether to continue or discontinue antifibrotic therapy after experiencing antifibrotic therapy-related adverse events.Read full original descriptionShow less
Understanding Pulmonary Fibrosis Through Web-Based Qualitative In-Depth Interviews on Antifibrotic TheRapy Decision-Making
This study will explore how adults in Japan with pulmonary fibrosis decide whether to continue or discontinue antifibrotic therapy after experiencing antifibrotic therapy-related adverse events.
Inclusion: Participants must meet all the following criteria to be eligible for inclusion in this study:; Pulmonary fibrosis (PF) participants in Japan. Note: This includes those clinically recognized as having idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF); Participants who are ≥18 years of age at the time of providing informed consent via the web-based system; Participants receiving outpatient care for pulmonary fibrosis (PF) who have been introduced to this study by a referring physician; Participants who have a history of taking, or are currently taking, pirfenidone, nintedanib, or nerandomilast; Participants who have experienced at least one antifibrotic (AF) therapy-related adverse event (AE); Discontinuation group only; Participants who have not received AF therapy for at least 1 month prior to enrollment; Participants whose AF therapy was discontinued within 6 months prior to enrollment; Participants whose reason for discontinuing AF therapy includes at least one AF therapy-related AE; Continuation group only; Participants who feel or have felt burdened by the experienced AE; Participants who have continued AF therapy for a specific period (≥6 months) at the time of enrollment.
Exclusion: Participants currently participating in any interventional clinical trials (regardless of the study drug, excluding observational studies); Participants who have undergone lung transplantation; Discontinuation group only 1) Participants who discontinued AF therapy solely for reasons other than AE (e.g., financial reasons, disease progression); Participants meeting any of the following criteria will be excluded from the study:; <!-- -->.